Pancreatic Cancer Research

ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Shuyang Pang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108326342. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 3

  1. ROCK1 regulates glycolysis in pancreatic cancer via the c-MYC/PFKFB3 pathway. Co-author DOI 10.1016/j.bbagen.2024.130669↗
  2. The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR signaling pathway. First author DOI 10.1007/s12094-021-02747-x↗
  3. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A. Co-author DOI 10.3892/ijo.2020.5120↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yiran Zhou · 2 shared papers, 2020–2024 · strength 0.38
  2. Changlin Zhou · 2 shared papers, 2020–2022 · strength 0.30
  3. Xuanning Chu · 1 shared paper, 2024 · strength 0.26
  4. B. Li · 1 shared paper, 2022 · strength 0.19
  5. Yu Zhou · 1 shared paper, 2022 · strength 0.19
  6. Baiyong Shen · 1 shared paper, 2022 · strength 0.19
  7. Duiyue Xu · 1 shared paper, 2020 · strength 0.12
  8. Baiyong Shen · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.